Enhanced antiproliferative activity of antibody-functionalized polymeric nanoparticles for targeted delivery of anti-miR-21 to HER2 positive gastric cancer

Wu, Fenglei; Zhang, Jian; Li, Wei; Bian, Baoxiang; Hong, Yidong; Song, Ziyan; Wang, Hui-Yu; Cui, Fangbo; Li, Rutian; Liu, Qin; Jiang, Xiaodong; Li, Xiaomin; Zheng, Junnian

doi:10.18632/oncotarget.18066

Cited by 26 publications

(13 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 In contrast, clear cell carcinoma showed poorer outcomes compared to the serous carcinoma in ESEOC patients in other studies. 17,20 The difference between the findings of this study and those of other studies could be justified by the fact that antineoplastic drug regimens affect the outcomes of different histologic types especially those of clear cell histology. 12 In contrast to previous studies, in this study, a few numbers of patients with clear cell carcinoma were included and were considered as having other types of tumors.…”

Section: Discussioncontrasting

confidence: 80%

“…29 The relationship between histological types and survival of EOC patients varied across studies. 2,11,17,20 The results of this research also indicated that patients with endometrioid type EOC had a worse OS than serous histological type. Also, the prognosis of the mucinous type was similar to that of the serous type.…”

Section: Discussionsupporting

confidence: 54%

“…15 In line with some previous observations, this study demonstrated that stage I ovarian cancer has a better clinical course than the other stages of ovarian cancer. 16,17 The average survival time in stage III and IV was significantly less than that of stage I in the current study. The decrease of OS in EOC patients as the stage advances has been reported by some previous studies.…”

Section: Discussioncontrasting

confidence: 43%

See 2 more Smart Citations

Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer

Khalafi-Nezhad

Ebrahimi

Ahmadpour

et al. 2020

CMAR

View full text Add to dashboard Cite

This study aimed to determine the prognostic factors influencing the overall survival (OS) of Iranian women with epithelial ovarian cancer (EOC). Methods: Information about newly diagnosed patients with confirmed EOC at Motahari Clinic, Shiraz, Iran, from January 1, 2001, to December 31, 2016, was retrospectively reviewed and analyzed. Cox-adjusted proportional hazards (PH) and stratified Cox (SC) models were used to determine the potential prognostic factors. Results: The mean (±SD) age at the diagnosis of 385 patients with EOC was 49.0 (±13.2) years old. Early-stage EOC (ESEOC) and advanced-stage EOC (ASEOC) were diagnosed in 34.3% and 65.7% of the total patients, respectively. The median (95% CI) OS was 35 (28−41) months. For ESEOC patients, a stage II-tumor led to a lower OS in the multivariable analysis compared to a lower stage tumor (P= 0.025). For ASEOC patients, age≥65 years at diagnosis (P=0.008) led to a lower OS. ASEOC patients with 2-5 parities (P=0.014) and >5 parity (P=0.001) demonstrated better OS than nulliparous women. Conclusion: Patients with ESEOC, higher tumor stage was associated with a shorter OS. The age at diagnosis harmed the OS of patients with ASEOC. More than one parity improved OS in ASEOC patients.

show abstract

Section: Discussioncontrasting

confidence: 80%

Section: Discussionsupporting

confidence: 54%

Section: Discussioncontrasting

confidence: 43%

See 1 more Smart Citation

Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer

Khalafi-Nezhad

Ebrahimi

Ahmadpour

et al. 2020

CMAR

View full text Add to dashboard Cite

show abstract

“…87 Gastric cancer tends to overexpress MiR-21; to combat this condition, Wu et al developed a novel nano-delivery system called anti-miRNA oligonucleotide-21-human epidermal growth factor receptorpoly(ethylene glycol)-poly(ε-caprolactone) nanoparticles, and then used it to encapsulate trastuzumab to target gastric cancer cells in vitro and in vivo. 88 As a result, gastric cancer cells were more sensitive to drugs, and this demonstrated the enormous potential of antibody-dependent targeted transport. In addition, Nam et al constructed a novel nanocarrier based on the mussel-inspired mineralization using calcium phosphate-assembled polymer nanocarrier to load DOX.…”

Section: Polymeric Micellesmentioning

confidence: 99%

Effects of major parameters of nanoparticles on their physical and chemical properties and recent application of nanodrug delivery system in targeted chemotherapy

Zhang¹,

Tang²,

Liu³

et al. 2017

IJN

132

View full text Add to dashboard Cite

Chemotherapy is still one of the main cancer therapy treatments, but the curative effect of chemotherapy is relatively low, as such the development of a new cancer treatment is highly desirable. The gradual maturation of nanotechnology provides an innovative perspective not only for cancer therapy but also for many other applications. There are a diverse variety of nanoparticles available, and choosing the appropriate carriers according to the demand is the key issue. The performance of nanoparticles is affected by many parameters, mainly size, shape, surface charge, and toxicity. Using nanoparticles as the carriers to realize passive targeting and active targeting can improve the efficacy of chemotherapy drugs significantly, reduce the mortality rate of cancer patients, and improve the quality of life of patients. In recent years, there has been extensive research on nanocarriers. In this review, the effects of several major parameters of nanoparticles on their physical and chemical properties are reviewed, and then the recent progress in the application of several commonly used nanoparticles is presented.

show abstract

“…89 Hu's team and Wu's team each introduced PCL-PEG nanoparticles coated with trastuzumab (HER-PEG-PCL NPs) to control the delivery of the inhibitor of miRNA. 12,90 These studies, respectively, verified the inhibitory function of miR-34a, miR-21, miR-542-3p, and miR-200c on GC in vitro or in vivo. Importantly, these strategies involve the use of synthetic nanoparticles and compounds to attempt to solve the problem of improving microRNAs-targeted transport to tumors so as to promote the clinical application of microRNA-based targeted therapies.…”

Section: Synthetic Nanoparticles and Compoundsmentioning

confidence: 75%

Research Progress in microRNA-Based Therapy for Gastric Cancer

Zhao

Shi

et al. 2019

OTT

View full text Add to dashboard Cite

Gastric cancer (GC) is one of the leading causes of tumor-related mortality. In addition to surgery and endoscopic resection, systemic therapy remains the main treatment option for GC, especially for advanced-stage disease and for cases not suitable for surgical therapy. Hence, improving the efficacy of systemic therapy is still an urgent problem to overcome. In the past decade, the essential roles of microRNAs (miRNAs) in tumor treatment have been increasingly recognized. In particular, miRNAs were recently shown to reverse the resistance to chemotherapy drugs such as 5-fluorouracil, cisplatin, and doxorubicin. Synthesized nanoparticles loaded with mimics or inhibitors of miRNAs can directly target tumor cells to suppress their growth. Moreover, exosomes may serve as promising safe carriers for mimics or inhibitors of miRNAs to treat GC. Some miRNAs have also been shown to play roles in the mechanism of action of other anti-tumor drugs. Therefore, in this review, we highlight the research progress on microRNA-based therapy in GC and discuss the challenges and prospects associated with this strategy. We believe that microRNA-based therapy has the potential to offer a clinical benefit to GC patients, and this review would contribute to and motivate further research to promote this field toward this ultimate goal.

show abstract

Enhanced antiproliferative activity of antibody-functionalized polymeric nanoparticles for targeted delivery of anti-miR-21 to HER2 positive gastric cancer

Cited by 26 publications

References 37 publications

<p>Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer</p>

<p>Parity as a Prognostic Factor in Patients with Advanced-Stage Epithelial Ovarian Cancer</p>

Effects of major parameters of nanoparticles on their physical and chemical properties and recent application of nanodrug delivery system in targeted chemotherapy

<p>Research Progress in microRNA-Based Therapy for Gastric Cancer</p>

Contact Info

Product

Resources

About